Holen Sie sich die Stockscreener-App
12.06
0.42%
0.05
Handel nachbörslich:
12.06
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer - Digital Health News
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment By Investing.com - Investing.com India
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment - Investing.com Australia
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story? - Sahm
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment - Yahoo Finance
Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua - Sahm
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Insider Selling: NovoCure (NASDAQ:NVCR) Insider Sells 1,100 Shares of Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CFO Sells $85,343.72 in Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CEO Sells $74,629.17 in Stock - MarketBeat
Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock - MarketBeat
NovoCure (NASDAQ:NVCR) COO Mukund Paravasthu Sells 43,246 Shares - MarketBeat
NVCR Crosses Above Key Moving Average Level - Nasdaq
Mukund Paravasthu sells Common shares via Morgan Stanley (NVCR) - Stock Titan
[144] NovoCure Ltd SEC Filing - Stock Titan
NovoCure Ltd. Hits Day Low of $11.80 Amid Price Pressure - Markets Mojo
Vanguard Group Inc. Sells 296,555 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Shares Bought by Quantbot Technologies LP - MarketBeat
NovoCure (NVCR) CMO sells shares to cover RSU tax withholding - Stock Titan
NovoCure (NVCR) CHRO sells 1,441 shares in tax withholding trade - Stock Titan
NovoCure (NVCR) COO offloads 1,963 shares in tax sell-to-cover - Stock Titan
Tax-withholding sale of 1,029 NovoCure (NASDAQ: NVCR) shares by ex-CMO - Stock Titan
NovoCure (NVCR) CEO reports RSU vesting and tax-cover share sales - Stock Titan
Equity awards and tax share withholding for NovoCure (NVCR) ex-CEO Cordova - Stock Titan
NovoCure (NASDAQ: NVCR) General Counsel receives 17,755-share performance award - Stock Titan
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update - Sahm
Novocure gains Japan reimbursement for Optune Lua device - Investing.com Australia
NovoCure Limited 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-03-02 - Seeking Alpha
NovoCure Ltd wins Japanese reimbursement approval for lung cancer treatment - Traders Union
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Novocure (NVCR) Gains Japanese Reimbursement Approval for Optune Lua - GuruFocus
Novocure (NVCR) Gains Approval for Optune Lua Reimbursement in J - GuruFocus
Novocure gains Japan reimbursement for Optune Lua device By Investing.com - Investing.com Canada
Japan’s health system to cover wearable lung cancer device Optune Lua - Stock Titan
Equities Analysts Set Expectations for NovoCure Q1 Earnings - MarketBeat
A Look At NovoCure (NVCR) Valuation As Record 2025 Results And Optune Pax Approval Reset Growth Expectations - Yahoo Finance
NovoCure Earnings Call: Growth Builds Amid Profit Strain - TipRanks
NovoCure Ltd. Opens with 6.47% Gain, Outpacing S&P 500's 0.69% Rise - Markets Mojo
NovoCure Shares Gap Down, Weak Start Raises Market Concerns - Markets Mojo
NovoCure Ltd. Hits Day High with 27.68% Surge in Stock Price - Markets Mojo
NovoCure Ltd. Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo
Is NovoCure (NVCR) Pricing Look Out Of Step With Recent Share Rebound - simplywall.st
NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile - simplywall.st
Hohimer Wealth Management LLC Takes Position in NovoCure Limited $NVCR - MarketBeat
Novocure CEO and CFO to field investor questions at Leerink event - Stock Titan
NovoCure Limited (NASDAQ:NVCR) Q4 2025 Earnings Call Transcript - Insider Monkey
Novocure to Participate in 2026 Leerink Global Healthcare Conference - Yahoo Finance
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
NovoCure (NASDAQ:NVCR) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS - MarketBeat
NovoCure (NVCR) Q4 Loss Narrowing Challenges Bearish Narrative On Persistent Unprofitability - simplywall.st
NovoCure: Q4 Earnings Snapshot - theheraldreview.com
NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
NovoCure Ltd (NVCR) Q4 2025 Earnings Call Highlights: Record Rev - GuruFocus
NovoCure Limited Q4 2025 Earnings Call Summary - Yahoo Finance
HC Wainwright & Co. Raises NovoCure (NVCR) Price Target to $49 | - GuruFocus
HC Wainwright Increases NovoCure (NASDAQ:NVCR) Price Target to $49.00 - MarketBeat
NVCR: Novocure Reports Strong Q4 Earnings and FDA Approval Boost - GuruFocus
NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
0.66%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):